Although there is an ongoing trail of BEZ235 (a dual PI3K - mTOR inhibitor) in combination with BKM120 [39], no clinical trial of BKM120+TKI258 in prostate cancer is being carried out. This evidence concerns the gene MTOR and Familial prostate cancer.